RETA+CAG

Description

RETA+CAG is a two-compound research blend combining Retatrutide (12.5 mg) and Cagrilintide (2.5 mg) in a single lyophilized vial, 15 mg total. Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors — a single lipidated peptide engineered to engage all three incretin-axis receptors at once. Cagrilintide is a long-acting lipidated amylin analog acting as a dual amylin and calcitonin receptor agonist (DACRA). Together they cover four distinct receptor pathways within energy-balance signaling, making the pairing a compact reference system for studying incretin–amylin co-agonism. It is supplied here for controlled analytical and laboratory investigation of multi-receptor metabolic signaling.

Research focus

• Combined GIP / GLP-1 / glucagon receptor and amylin-receptor activation
• Incretin–amylin co-agonist models and receptor cross-talk
• Comparison with single-agent Retatrutide, Cagrilintide and GLP-1/amylin pairings (e.g. semaglutide + cagrilintide)

This Medtruva catalog product is a laboratory research material, not a clinical product. Store and prepare it only according to an appropriate research protocol, and review all available documentation before use.

For laboratory research use only. Not for human consumption, diagnosis, treatment, or veterinary use.